Mounjaro KwikPen 2.5mg (Tirzepatide)

Mounjaro KwikPen 2.5mg (Tirzepatide)

Mounjaro KwikPen 2.5mg is a genuine Eli Lilly pre-filled pen injector containing Tirzepatide — a dual GLP-1 receptor and GIP receptor co-agonist — supplied by PeptideCores as an authorised European distributor. Each Mounjaro KwikPen delivers 4 weekly doses of 2.5mg Tirzepatide via a precision single-use needle injection mechanism. The 2.5mg dose is the starting strength in the Mounjaro dosing range, designed as the initial weekly dose for the first 4 weeks before dose escalation to 5mg. PeptideCores supplies genuine Mounjaro KwikPen with full Eli Lilly product documentation and EU cold pack shipping within 24 hours of order confirmation.

What is Mounjaro (Tirzepatide)?

Mounjaro is the brand name for Tirzepatide — a once-weekly dual GLP-1 receptor and GIP receptor co-agonist developed by Eli Lilly. Tirzepatide is a 39 amino acid acylated peptide with molecular weight 4813.47 g/mol that simultaneously activates both the glucagon-like peptide-1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIPR). This dual receptor engagement produces synergistic incretin effects beyond what single GLP-1R agonists like Semaglutide can achieve — combining GLP-1R-mediated insulin secretion, glucagon suppression and appetite signalling with GIPR-mediated incretin amplification and adipose tissue metabolic effects in a single weekly injection.

Mounjaro KwikPen — How It Works

The Mounjaro KwikPen is a single-use pre-filled auto-injector pen containing Tirzepatide in solution at the specified dose strength. Each pen is pre-set to deliver a precise 2.5mg dose of Tirzepatide per injection. The KwikPen features a hidden needle that deploys automatically on use, a dose confirmation window and an audible click to confirm complete injection. The pen body is clearly labelled with the dose strength, batch number, expiry date and Eli Lilly product information. Each KwikPen delivers one single dose — one pen per weekly injection.

Dual GLP-1R and GIPR Mechanism

Tirzepatide in Mounjaro acts simultaneously at both GLP-1R and GIPR — two pharmacologically distinct receptors with complementary intracellular signalling pathways. GLP-1R activation via Gs protein coupling increases intracellular cAMP and activates downstream insulin secretory mechanisms in pancreatic beta cells. GIPR activation adds a second cAMP-mediated amplification pathway operating independently of GLP-1R, producing synergistic insulin secretion enhancement. Beyond pancreatic effects, GLP-1R activation also drives central appetite suppression via hypothalamic and brainstem receptor expression, while GIPR co-agonism adds direct effects on adipose tissue lipid metabolism and adipocyte biology not seen with selective GLP-1R agonism alone.

Mounjaro 2.5mg — Starting Dose

The 2.5mg KwikPen is the recommended starting strength in the Mounjaro dosing schedule. The 2.5mg weekly dose is maintained for the first 4 weeks before dose escalation to the 5mg strength. Subsequent escalation from 5mg proceeds at 4-weekly intervals through 7.5mg, 10mg, 12.5mg and 15mg depending on individual tolerability and response. The 2.5mg starting dose allows gradual introduction to dual incretin receptor co-agonism and is available from PeptideCores as a standalone supply for the initial phase of a Mounjaro protocol.

Mounjaro KwikPen Range at PeptideCores

PeptideCores supplies Mounjaro KwikPen across the full dose range as an authorised European distributor. Available strengths include 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg — allowing complete coverage of the full Mounjaro escalation schedule from a single trusted supplier. Each strength is supplied as genuine Eli Lilly product with full documentation, cold pack shipping and EU-wide delivery within 24 hours.

For researchers comparing the dual GLP-1R/GIPR mechanism of Tirzepatide with the triple GLP-1R/GIPR/GCGR mechanism of Retatrutide, PeptideCores also supplies Retatrutide in multiple pen formats including the Retatrutide 40mg R&D pen, Retatrutide 40mg x2 Bundle, Alluvi Retatrutide 20mg and Alluvi Retatrutide 40mg pens — enabling full comparative incretin research across the complete mono, dual and triple agonist spectrum.

Product Specifications

Product name — Mounjaro KwikPen 2.5mg
Active compound — Tirzepatide 2.5mg
Manufacturer — Eli Lilly
Distribution — PeptideCores — authorised European distributor
Format — Pre-filled single-use auto-injector KwikPen
Dose per pen — 2.5mg Tirzepatide
Doses per pen — 1 dose per pen (4 pens per box)
Receptor targets — GLP-1R and GIPR dual co-agonist
Molecular weight — 4813.47 g/mol
Dosing frequency — Once weekly
Storage — Refrigerated 2 to 8°C — do not freeze
Shipping — EU-wide dispatched within 24 hours with cold pack
Documentation — Full Eli Lilly product documentation included

Storage and Handling

Mounjaro KwikPen must be stored refrigerated at 2 to 8°C and must not be frozen. Keep away from direct light and heat. Do not use if the pen has been frozen or if the solution appears cloudy, discoloured or contains particles. Remove from refrigerator 30 minutes before use and allow to reach room temperature. After removal from refrigerator Mounjaro KwikPen can be kept at room temperature below 30°C for up to 21 days. All PeptideCores Mounjaro orders are dispatched with cold pack packaging to maintain temperature integrity during transit to European destinations.

Shipping Across Europe

PeptideCores dispatches Mounjaro KwikPen 2.5mg to all European destinations — UK, Germany, France, Netherlands, Spain, Italy, Belgium, Austria, Sweden, Denmark, Poland, Greece, Portugal, Ireland and all other EU countries — within 24 hours of order confirmation. Cold pack packaging is included as standard on all Mounjaro orders. Full tracking is provided from dispatch through to delivery and all European customer data is handled in strict GDPR compliance. Discreet packaging with no reference to contents on the outer packaging is standard on every shipment.